CSPM EDP Sciences logo
Access to submission and peer review system
Search
Menu
All issues Volume 2 (2021) Vis Cancer Med, 2 (2021) 6 References
Open Access
Review
Issue
Vis Cancer Med
Volume 2, 2021
Article Number 6
Number of page(s) 4
DOI https://doi.org/10.1051/vcm/2021005
Published online 01 December 2021
  1. Yoon JU, Byeon GJ, Park JY, et al. Bloodless living donor liver transplantation: risk factors, outcomes, and diagnostic predictors. Medicine (Baltimore) 2018;97(50):e13581. [CrossRef] [PubMed] [Google Scholar]
  2. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394–424. [CrossRef] [PubMed] [Google Scholar]
  3. Global Burden of Disease Cancer C, Fitzmaurice C, Abate D, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study. JAMA Oncol. 2019;5(12):1749–1768. [CrossRef] [PubMed] [Google Scholar]
  4. Global Burden of Disease Liver Cancer C Akinyemiju T, Abera S, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the Global Burden of Disease Study 2015. JAMA Oncol 2017;3(12):1683–1691. [CrossRef] [PubMed] [Google Scholar]
  5. Martel G, Hawel J, Rekman J, et al. Liver resection for non-colorectal, non-carcinoid, non-sarcoma metastases: a multicenter study. PLoS One 2015;10(3):e0120569. [CrossRef] [PubMed] [Google Scholar]
  6. Uggeri F, Ronchi PA, Goffredo P, et al. Metastatic liver disease from non-colorectal, non-neuroendocrine, non-sarcoma cancers: a systematic review. World J Surg Oncol. 2015;13:191. [CrossRef] [PubMed] [Google Scholar]
  7. European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018;69(1):182–236. [CrossRef] [PubMed] [Google Scholar]
  8. Tsilimigras DI, Brodt P, Clavien P-A, et al. Liver metastases. Nat Rev Dis Primers 2021;7(1):27. [CrossRef] [PubMed] [Google Scholar]
  9. Starzl TE, Marchioro TL, Vonkaulla KN, et al. Homotransplantation of the liver in humans. Surg Gynecol Obstet 1963;117:659–676. [PubMed] [Google Scholar]
  10. Merion RM, Schaubel DE, Dykstra DM, et al. The survival benefit of liver transplantation. Am J Transplant 2005;5(2):307–313. [CrossRef] [PubMed] [Google Scholar]
  11. Dawwas MF, Gimson AE, Lewsey JD, et al. Survival after liver transplantation in the United Kingdom and Ireland compared with the United States. Gut 2007;56(11):1606–1613. [CrossRef] [PubMed] [Google Scholar]
  12. Adam R, Karam V, Delvart V, et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol 2012;57(3):675–688. [CrossRef] [PubMed] [Google Scholar]
  13. European Association for the Study of the Liver. Electronic address EEE. EASL Clinical Practice Guidelines: Liver transplantation. J Hepatol 2016;64(2):433–485. [CrossRef] [PubMed] [Google Scholar]
  14. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. New England J Med 1996;334(11):693–699. [CrossRef] [PubMed] [Google Scholar]
  15. Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003;124(1):91–96. [CrossRef] [PubMed] [Google Scholar]
  16. de Rougemont O, Dutkowski P, Clavien PA. Biological modulation of liver ischemia-reperfusion injury. Curr Opin Organ Transplant 2010;15(2):183–189. [CrossRef] [PubMed] [Google Scholar]
  17. Zhai Y, Petrowsky H, Hong JC, Busuttil RW, Kupiec-Weglinski JW. Ischaemia-reperfusion injury in liver transplantation – from bench to bedside. Nat Rev Gastroenterol Hepatol 2013;10(2):79–89. [CrossRef] [PubMed] [Google Scholar]
  18. Ito T, Naini BV, Markovic D, et al. Ischemia-reperfusion injury and its relationship with early allograft dysfunction in liver transplant patients. Am J Transplant 2020;21(2):614–625. [Google Scholar]
  19. Dar WA, Sullivan E, Bynon JS, et al. Ischaemia reperfusion injury in liver transplantation: Cellular and molecular mechanisms. Liver Int 2019;39(5):788–801. [CrossRef] [PubMed] [Google Scholar]
  20. Reiniers MJ, van Golen RF, van Gulik TM, et al. Reactive oxygen and nitrogen species in steatotic hepatocytes: a molecular perspective on the pathophysiology of ischemia-reperfusion injury in the fatty liver. Antioxid Redox Signal 2014;21(7):1119–1142. [CrossRef] [PubMed] [Google Scholar]
  21. Bamboat ZM, Balachandran VP, Ocuin LM, et al. Toll-like receptor 9 inhibition confers protection from liver ischemia-reperfusion injury. Hepatology 2010;51(2):621–632. [CrossRef] [PubMed] [Google Scholar]
  22. Cursio R, Colosetti P, Gugenheim J. Autophagy and liver ischemia-reperfusion injury. Biomed Res Int 2015;2015:17590. [Google Scholar]
  23. Yang YY, Lee PC, Huang YT, Lee WP, et al. Involvement of the HIF-1alpha and Wnt/beta-catenin pathways in the protective effects of losartan on fatty liver graft with ischaemia/reperfusion injury. Clin Sci (Lond) 2014;126(2):163–174. [CrossRef] [PubMed] [Google Scholar]
  24. van Rijn R, Schurink IJ, de Vries Y, et al. Hypothermic machine perfusion in liver transplantation – a randomized trial. N Engl J Med 2021;384(15):1391–1401. [CrossRef] [PubMed] [Google Scholar]
  25. Kron P, Schlegel A, Mancina L, et al. Hypothermic oxygenated perfusion (HOPE) for fatty liver grafts in rats and humans. J Hepatol 2017;S0168-8278(17)32268-7. [PubMed] [Google Scholar]
  26. Bruinsma BG, Yeh H, Ozer Set al. Subnormothermic machine perfusion for ex vivo preservation and recovery of the human liver for transplantation. Am J Transplant 2014;14(6):1400–1409. [CrossRef] [PubMed] [Google Scholar]
  27. Hoyer DP, Mathe Z, Gallinat A, et al. Controlled oxygenated rewarming of cold stored livers prior to transplantation: first clinical application of a new concept. Transplantation 2016;100(1):147–152. [CrossRef] [PubMed] [Google Scholar]
  28. Nasralla D, Coussios CC, Mergental H, et al. A randomized trial of normothermic preservation in liver transplantation. Nature 2018;557(7703):50–56. [CrossRef] [PubMed] [Google Scholar]
  29. He X, Guo Z, Zhao Q, et al. The first case of ischemia-free organ transplantation in humans: a proof of concept. Am J Transplant 2018;18(3):737–744. [CrossRef] [PubMed] [Google Scholar]
  30. He X, Chen G, Zhu Z, et al. The first case of ischemia-free kidney transplantation in humans. Front Med (Lausanne) 2019;6:276. [CrossRef] [PubMed] [Google Scholar]
  31. Lund LH, Khush KK, Cherikh WS, et al. The registry of the International Society for Heart and Lung Transplantation: Thirty-fourth Adult Heart Transplantation Report-2017; focus theme: allograft ischemic time. J Heart Lung Transplant 2017;36(10):1037–1046. [CrossRef] [PubMed] [Google Scholar]
  32. Zhang Z, Tang Y, Zhao Qet al. Association of perfusion characteristics and posttransplant liver function in ischemia-free liver transplantation. Liver Transpl 2020;26(11):1441–1454. [CrossRef] [PubMed] [Google Scholar]
  33. Guo Z, Zhao Q, Huang S, et al. Ischaemia-free liver transplantation in humans: a first-in-human trial. Lancet Reg Health West Pac. 2021;16:100260. [CrossRef] [PubMed] [Google Scholar]
  34. Clinical and Translational Medicine. 2021 (in press). [Google Scholar]
  35. Oldani G, Crowe LA, Orci LA, et al. Pre-retrieval reperfusion decreases cancer recurrence after rat ischemic liver graft transplantation. J Hepatol 2014;61(2):278–285. [CrossRef] [PubMed] [Google Scholar]
  36. Kornberg A, Witt U, Kornberg J, et al. Treating ischaemia-reperfusion injury with prostaglandin E1 reduces the risk of early hepatocellular carcinoma recurrence following liver transplantation. Aliment Pharmacol Ther 2015;42(9):1101–1110. [CrossRef] [PubMed] [Google Scholar]
  37. Nagai S, Yoshida A, Facciuto Met al. Ischemia time impacts recurrence of hepatocellular carcinoma after liver transplantation. Hepatology (Baltimore, MD) 2015;61(3):895–904. [CrossRef] [PubMed] [Google Scholar]
  38. van Leeuwen OB, Ubbink R, de Meijer VE, et al. The first case of ischemia-free organ transplantation in humans: A proof of concept. Am J Transplant 2018;18(8):2091. [CrossRef] [PubMed] [Google Scholar]
  39. Quintini C, Diago Uso T, Liu Q. Ischemia-free liver transplantation: Will the diamond with a flaw replace the pebble without? Liver Transpl 2020;26(11):1391–1392. [CrossRef] [PubMed] [Google Scholar]
  40. Jayant K, Reccia I, Shapiro AMJ. Normothermic ex-vivo liver perfusion: Where do we stand and where to reach? Expert Rev Gastroenterol Hepatol 2018;12(10):1045–1058. [CrossRef] [PubMed] [Google Scholar]
  41. Kim J, Zimmerman MA, Hong JC. Emerging innovations in liver preservation and resuscitation. Transplant Proc 2018;50(8):2308–2316. [CrossRef] [PubMed] [Google Scholar]
  42. Mueller M, Hefti M, Eshmuminov D, et al. Long-term normothermic machine preservation of partial livers: first experience with 21 human hemi-livers. Ann Surg 2021;274(5):836–842. [CrossRef] [PubMed] [Google Scholar]
  43. Liu Q, Berendsen T, Izamis ML, et al. Perfusion defatting at subnormothermic temperatures in steatotic rat livers. Transplant Proc 2013;45(9):3209–3213. [CrossRef] [PubMed] [Google Scholar]
  44. Boteon YL, Stephenson BTF, Neil DAH, et al. Lipid metabolism and functional assessment of discarded human livers with steatosis undergoing 24 hours of normothermic machine perfusion. Liver Transpl 2018;24(5):708–709. [CrossRef] [PubMed] [Google Scholar]
  45. Verstegen MMA, Mezzanotte L, Ridwan RY, et al. First report on ex vivo delivery of paracrine active human mesenchymal stromal cells to liver grafts during machine perfusion. Transplantation 2020;104(1):e5–e7. [CrossRef] [PubMed] [Google Scholar]
  46. Chiang CH, Wu CP, Perng WC, et al. Use of anti-(tumour necrosis factor-alpha) antibody or 3-deaza-adenosine as additives to promote protection by University of Wisconsin solution in ischaemia/reperfusion injury. Clin Sci (Lond) 2000;99(3):215–222. [CrossRef] [PubMed] [Google Scholar]
  47. Donckier V, Troisi R, Le Moine A, et al. Early immunosuppression withdrawal after living donor liver transplantation and donor stem cell infusion. Liver Transpl 2006;12(10):1523–1528. [CrossRef] [PubMed] [Google Scholar]
  48. Nassar A, Liu Q, Farias K, et al. Role of vasodilation during normothermic machine perfusion of DCD porcine livers. Int J Artif Organs 2014;37(2):165–172. [CrossRef] [PubMed] [Google Scholar]
  49. Zhao Q, Nie Y, Guo Z, et al. The future of organ-oriented research and treatment. Hepatobiliary Surg Nutr 2019;8(5):502–505. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.